November 21, 2017 / 2:41 PM / in a year

BRIEF-Oncology Venture Sweden approves recommended dose for LiPlaCis

Nov 21 (Reuters) - ONCOLOGY VENTURE SWEDEN AB:

* ‍DOSE OF 75MG + 75MG PER PATIENT ON DAYS 1 AND 8 IN A THREE WEEKS SCHEDULE WAS FOUND SAFE

* DOSE ‍WAS APPROVED BY DATA SAFETY COMMITTEE AS RECOMMENDED DOSE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below